Citations to this article

Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, Stefano Grosso, Francesca Molinari, Teresa Macarulla, Mariangela Russo, Carlotta Cancelliere, Davide Zecchin, Luca Mazzucchelli, Takehiko Sasazuki, Senji Shirasawa, Massimo Geuna, Milo Frattini, José Baselga, Margherita Gallicchio, Stefano Biffo, Alberto Bardelli
Published in Volume 120, Issue 8
J Clin Invest. 2010; 120(8):2858–2866 doi:10.1172/JCI37539

Total citations by year in Crossref

Year: 2013 2012 2011 2010 Total
Citations: 1 9 17 1 28
Citation information

Citations to this article in Crossref (28)

Title and authors Publication Year
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients
B Karakas, D Colak, N Kaya, H Ghebeh, A Al-Qasem, F Hendrayani, M Toulimat, T Al-Tweigeri, BH Park, A Aboussekhra
Cancer biology & therapy 2013
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
DL Reidy-Lagunes, E Vakiani, MF Segal, EM Hollywood, LH Tang, DB Solit, MC Pietanza, M Capanu, LB Saltz
Cancer 2012
Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer
S Keck, AC Glencer, HS Rugo
Future Oncology 2012
Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma
C Rodríguez-Antona, J García-Donas
Pharmacogenomics 2012
Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma
L Du, J Shen, A Weems, SL Lu
Journal of Oncology 2012
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
AM Gonzalez-Angulo, GR Blumenschein
Cancer Treatment Reviews 2012
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas
F Wei, Y Liu, AC Bellail, JJ Olson, SY Sun, G Lu, L Ding, C Yuan, G Wang, C Hao
Cancer Letters 2012
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
L Willems, J Tamburini, N Chapuis, C Lacombe, P Mayeux, D Bouscary
Current Oncology Reports 2012
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
D Lipson, M Capelletti, R Yelensky, G Otto, A Parker, M Jarosz, JA Curran, S Balasubramanian, T Bloom, KW Brennan, A Donahue, SR Downing, GM Frampton, L Garcia, F Juhn, KC Mitchell, E White, J White, Z Zwirko, T Peretz, H Nechushtan, L Soussan-Gutman, J Kim, H Sasaki, HR Kim, S Park, D Ercan, CE Sheehan, JS Ross, MT Cronin, PA Jänne, PJ Stephens
Nature Medicine 2012
Phase II trial of temsirolimus in patients with metastatic breast cancer
GF Fleming, CX Ma, D Huo, H Sattar, M Tretiakova, L Lin, OM Hahn, FO Olopade, R Nanda, PC Hoffman, MJ Naughton, T Pluard, SD Conzen, MJ Ellis
Breast Cancer Research and Treatment 2012
Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells
KM Müller, IH Tveteraas, M Aasrum, J Ødegård, M Dawood, O Dajani, T Christoffersen, DL Sandnes
BMC Cancer 2011
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy
AM Martelli, G Tabellini, F Ricci, C Evangelisti, F Chiarini, R Bortul, JA McCubrey, FA Manzoli
Advances in Enzyme Regulation 2011
mTOR as a therapeutic target in patients with gastric cancer
SE Al-Batran, M Ducreux, A Ohtsu
International Journal of Cancer 2011
Somatic Mutations in PIK3CA and Activation of AKT in Intraductal Tubulopapillary Neoplasms of the Pancreas :
H Yamaguchi, Y Kuboki, T Hatori, M Yamamoto, K Shiratori, S Kawamura, M Kobayashi, M Shimizu, S Ban, I Koyama, M Higashi, N Shin, K Ishida, T Morikawa, F Motoi, M Unno, A Kanno, K Satoh, T Shimosegawa, H Orikasa, T Watanabe, K Nishimura, Y Harada, T Furukawa
American Journal of Surgical Pathology 2011
Liposarcoma: Molecular Genetics and Therapeutics
R Conyers, S Young, DM Thomas
Sarcoma 2011
Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies
Z Walther, J Sklar
The Cancer Journal 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
C Delbaldo, S Albert, C Dreyer, MP Sablin, M Serova, E Raymond, S Faivre
Targeted Oncology 2011
Impairment of Cytoplasmic eIF6 Activity Restricts Lymphomagenesis and Tumor Progression without Affecting Normal Growth
A Miluzio, A Beugnet, S Grosso, D Brina, M Mancino, S Campaner, B Amati, A de Marco, S Biffo
Cancer Cell 2011
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
WD Roock, VD Vriendt, N Normanno, F Ciardiello, S Tejpar
The Lancet Oncology 2011
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
SA Wander, BT Hennessy, JM Slingerland
Journal of Clinical Investigation 2011
The Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation
MC Mendoza, EE Er, J Blenis
Trends in Biochemical Sciences 2011
mTOR Inhibitors in Advanced Renal Cell Carcinoma
MH Voss, AM Molina, RJ Motzer
Hematology/Oncology Clinics of North America 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, F Stivala, M Donia, P Fagone, F Nicoletti, M Libra, P Ruvolo, V Ruvolo, C Evangelisti, AM Martelli, JA McCubrey
Leukemia 2011
Current and future directions in mammalian target of rapamycin inhibitors development
A Fasolo, C Sessa
Expert Opinion on Investigational Drugs 2011
Mechanisms of mTOR inhibitor resistance in cancer therapy
JS Carew, KR Kelly, ST Nawrocki
Targeted Oncology 2011

Advertisement